Bevacizumab in the treatment of high-grade gliomas: An overview

Angiogenesis

Volumn 14, Issue 4, 2011, Pages 423-430

  Kunnakkat, Saroj ^a   Narayana, Ashwatha ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; Bevacizumab; High grade glioma; VEGF

Indexed keywords

BEVACIZUMAB; IRINOTECAN; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR 1; PLATELET DERIVED GROWTH FACTOR 2; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; BRAIN HEMORRHAGE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURVIVAL; CHEMORADIOTHERAPY; DEEP VEIN THROMBOSIS; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG MEGADOSE; FATIGUE; GLIOMA; HUMAN; LUNG EMBOLISM; MORBIDITY; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN FUNCTION; QUALITY OF LIFE; RASH; REVIEW; THROMBOCYTOPENIA; TUMOR VASCULARIZATION; WOUND HEALING IMPAIRMENT;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN NEOPLASMS; GLIOMA; HUMANS; MICE; NEOVASCULARIZATION, PATHOLOGIC; QUALITY OF LIFE; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84855186726     PISSN: 09696970     EISSN: 15737209     Source Type: Journal    
DOI: 10.1007/s10456-011-9232-2     Document Type: Review

References (43)

1. National Cancer Institute (2010) Brain tumor. National Institutes of Health. http://www.cancer.gov/cancertopics/types/brain. Accessed 8 May 2011
2. Narayana A, Recht L, Gutin PH (2010) Central nervous system tumors. In: Hoppe RT, Philips TL, Roach M (eds) Textbook of radiation oncology. Saunders, Philadelphia, pp 421-432
3. JJ Bernstein CA Woodard 1995 Glioblastoma cells do not intravasate into blood vessels Neurosurgery 36 1 124 132 7708148 10.1227/00006123-199501000-00016 1:STN:280:DyaK2M3itlCitA%3D%3D discussion 132
4. SJ Harper DO Bates 2008 VEGF-A splicing: the key to anti-angiogenic therapeutics? Nat Rev Cancer 8 11 880 887 18923433 10.1038/nrc2505 1:CAS:528:DC%2BD1cXht1yjtbnF
5. H Kawamura X Li SJ Harper DO Bates L Claesson-Welsh 2008 Vascular endothelial growth factor (VEGF)-A165b is a weak in vitro agonist for VEGF receptor-2 due to lack of coreceptor binding and deficient regulation of kinase activity Cancer Res 68 12 4683 4692 10.1158/0008-5472.can-07-6577 18559514 10.1158/0008-5472.CAN-07-6577 1:CAS:528:DC%2BD1cXnt1aqur0%3D
6. DJ Hicklin LM Ellis 2005 Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis J Clin Oncol 23 5 1011 1027 10.1200/jco.2005.06.081 15585754 10.1200/JCO.2005.06.081 1:CAS:528: DC%2BD2MXit1Gnsro%3D (Pubitemid 46202320)
7. KJ Kim B Li J Winer M Armanini N Gillett HS Phillips N Ferrara 1993 Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo Nature 362 6423 841 844 7683111 10.1038/362841a0 1:CAS:528:DyaK3sXktVKju7s%3D (Pubitemid 23132159)
8. N Ferrara KJ Hillan H-P Gerber W Novotny 2004 Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer Nat Rev Drug Discov 3 5 391 400 15136787 10.1038/nrd1381 1:CAS:528:DC%2BD2cXktlCrt78%3D (Pubitemid 38618122)
9. DF Stefanik WK Fellows LR Rizkalla WM Rizkalla PP Stefanik AB Deleo WC Welch 2001 Monoclonal antibodies to vascular endothelial growth factor (VEGF) and the VEGF receptor, FLT-1, inhibit the growth of C6 glioma in a mouse xenograft J Neurooncol 55 2 91 100 10.1023/a:1013329832067 11817706 10.1023/A:1013329832067 1:STN:280:DC%2BD38%2FovF2ktw%3D%3D (Pubitemid 34065325)
10. V Mathieu N De Neve M Le Mercier J Dewelle JF Gaussin M Dehoux R Kiss F Lefranc 2008 Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model Neoplasia 10 12 1383 1392 19048117 1:CAS:528:DC%2BD1MXhvVWht7g%3D
11. JF de Groot G Fuller AJ Kumar Y Piao K Eterovic Y Ji CA Conrad 2010 Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice Neuro-Oncology 12 3 233 242 10.1093/neuonc/nop027 20167811
12. ET Wong KR Hess MJ Gleason KA Jaeckle AP Kyritsis MD Prados VA Levin WKA Yung 1999 Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials J Clin Oncol 17 8 2572 10561324 1:STN:280:DC%2BD3c%2FjtVSmsQ%3D%3D
13. JJ Vredenburgh A Desjardins JE Herndon JM Dowell DA Reardon JA Quinn JN Rich S Sathornsumetee S Gururangan M Wagner DD Bigner AH Friedman HS Friedman 2007 Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma Clin Cancer Res 13 4 1253 1259 10.1158/1078-0432.ccr-06-2309 17317837 10.1158/1078-0432.CCR-06-2309 1:CAS:528:DC%2BD2sXhvF2htr8%3D (Pubitemid 46424067)
14. W Chen S Delaloye DHS Silverman C Geist J Czernin J Sayre N Satyamurthy W Pope A Lai ME Phelps T Cloughesy 2007 Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study J Clin Oncol 25 30 4714 4721 10.1200/jco.2006.10.5825 17947718 10.1200/JCO.2006.10.5825 1:CAS:528:DC%2BD2sXhtlCgsLjL (Pubitemid 350086472)
15. A Narayana P Kelly J Golfinos E Parker G Johnson E Knopp D Zagzag I Fischer S Raza P Medabalmi P Eagan ML Gruber 2009 Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival J Neurosurg 110 1 173 180 10.3171/2008.4.17492 18834263 10.3171/2008.4.17492
16. AD Norden GS Young K Setayesh A Muzikansky R Klufas GL Ross AS Ciampa LG Ebbeling B Levy J Drappatz S Kesari PY Wen 2008 Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence Neurology 70 10 779 787 10.1212/01.wnl.0000304121.57857.38 18316689 10.1212/01.wnl. 0000304121.57857.38 1:CAS:528:DC%2BD1cXitlyqs7o%3D
17. Gilbert MR, Wang M, Aldape K, Lassman A, Sorensen AG, Mikkelsen T, Groves M, Werner-Wasik M, Regine W, Mehta M (2009) RTOG 0625: a phase II study of bevacizumab with irinotecan in recurrent glioblastoma (GBM). J Clin Oncol 27 [15s (suppl; abstr 2011)]
18. HS Friedman MD Prados PY Wen T Mikkelsen D Schiff LE Abrey WKA Yung N Paleologos MK Nicholas R Jensen J Vredenburgh J Huang M Zheng T Cloughesy 2009 Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma J Clin Oncol 27 28 4733 4740 10.1200/jco.2008.19.8721 19720927 10.1200/JCO.2008.19.8721 1:CAS:528:DC%2BD1MXhtlGgtbbM
19. M Prados T Cloughesy M Samant L Fang PY Wen T Mikkelsen D Schiff LE Abrey WKA Yung N Paleologos MK Nicholas R Jensen J Vredenburgh A Das HS Friedman 2011 Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab Neuro-Oncology 13 1 143 151 10.1093/neuonc/noq151 21084434 10.1093/neuonc/noq151 1:CAS:528:DC%2BC3MXhvFOiurw%3D
20. D Zagzag R Amirnovin MA Greco H Yee J Holash SJ Wiegand S Zabski GD Yancopoulos M Grumet 2000 Vascular apoptosis and involution in gliomas precede neovascularization: a novel concept for glioma growth and angiogenesis Lab Invest 80 6 837 849 10879735 1:STN:280:DC%2BD3czjs1SrsA%3D%3D (Pubitemid 30421801)
21. RK Jain 2001 Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy Nat Med 7 9 987 989 11533692 10.1038/nm0901-987 1:CAS:528:DC%2BD3MXmvFOmsrc%3D (Pubitemid 32937367)
22. R Jain E di Tomaso D Duda J Loeffler A Sorensen T Batchelor 2007 Angiogenesis in brain tumours Nat Rev Neurosci 8 610 622 17643088 10.1038/nrn2175 1:CAS:528:DC%2BD2sXnvFKntbk%3D (Pubitemid 47093931)
23. PH Gutin FM Iwamoto K Beal NA Mohile S Karimi BL Hou S Lymberis Y Yamada J Chang LE Abrey 2009 Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas Int J Radiat Oncol Biol Phys 75 1 156 163 19167838 10.1016/j.ijrobp.2008.10.043 1:CAS:528: DC%2BD1MXhtVegsLjO
24. A Narayana JG Golfinos I Fischer S Raza P Kelly E Parker EA Knopp P Medabalmi D Zagzag P Eagan ML Gruber 2008 Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma Int J Radiat Oncol Biol Phys 72 2 383 389 18793954 10.1016/j.ijrobp.2008.05.062 1:CAS:528:DC%2BD1cXhtFWlsL7J
25. Narayana A, Gruber D, Kunnakkat S, Golfinos J, Parker E, Raza S, Zagzag D, Eagan P, Gruber ML (2011) A clinical trial of bevacizumab, temozolomide, and radiation for newly-diagnosed glioblastoma multiforme. J Neurosurg (in press)
26. A Lai A Tran PL Nghiemphu WB Pope OE Solis M Selch E Filka WH Yong PS Mischel LM Liau S Phuphanich K Black S Peak RM Green CE Spier T Kolevska J Polikoff L Fehrenbacher R Elashoff T Cloughesy 2011 Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme J Clin Oncol 29 2 142 148 10.1200/jco.2010.30.2729 21135282 10.1200/JCO.2010.30.2729 1:CAS:528: DC%2BC3MXhvVahtb0%3D
27. Chinot O, de La Motte Rouge T, Moore N, Zeaiter A, Das A, Phillips H, Modrusan Z, Cloughesy T (2011) AVAglio: phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Adv Ther 1-7. doi: 10.1007/s12325-011-0007-3
28. Halperin E, Constine L, Tarbell N, Kun L (2004) Pediatric radiation oncology. Lippincott Williams & Wilkins, Philadelphia
29. A Narayana S Kunnakkat J Chacko-Mathew S Gardner M Karajannis S Raza J Wisoff H Weiner D Harter J Allen 2010 Bevacizumab in recurrent high-grade pediatric gliomas Neuro-Oncology 12 9 985 990 10.1093/neuonc/noq033 20363768 10.1093/neuonc/noq033 1:CAS:528:DC%2BC3cXhtVGrsbnL
30. S Gururangan SN Chi T Young Poussaint A Onar-Thomas RJ Gilbertson S Vajapeyam HS Friedman RJ Packer BN Rood JM Boyett LE Kun 2010 Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a pediatric brain tumor consortium study J Clin Oncol 28 18 3069 3075 10.1200/jco.2009.26.8789 20479404 10.1200/JCO.2009.26.8789 1:CAS:528:DC%2BC3cXptlaju7k%3D
31. W Zhang Y Lin B Chen S Song T Jiang 2010 Recurrent glioblastoma of childhood treated with bevacizumab: case report and molecular features Child's Nerv Syst 26 1 137 143 10.1007/s00381-009-0995-3 10.1007/s00381-009-0995-3
32. Parekh C, Jubran R, Erdreich-Epstein A, Panigrahy A, Bluml S, Finlay J, Dhall G (2010) Treatment of children with recurrent high grade gliomas with a bevacizumab containing regimen. J Neuro-Oncol 1-8. doi: 10.1007/s11060-010-0444- x
33. SR Nalluri D Chu R Keresztes X Zhu S Wu 2008 Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients JAMA 300 19 2277 2285 10.1001/jama.2008.656 19017914 10.1001/jama.2008.656 1:CAS:528:DC%2BD1cXhtlyrt77O
34. LC Marras WH Geerts JR Perry 2000 The risk of venous thromboembolism is increased throughout the course of malignant glioma Cancer 89 3 640 646 10.1002/1097-0142(20000801)89:3<640::aid-cncr20>3.0.co;2-e 10931464 10.1002/1097-0142(20000801)89:3<640::AID-CNCR20>3.0.CO;2-E 1:STN:280:DC%2BD3cvgt1aqsg%3D%3D (Pubitemid 30640111)
35. TN Kreisl L Kim K Moore P Duic C Royce I Stroud N Garren M Mackey JA Butman K Camphausen J Park PS Albert HA Fine 2009 Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma J Clin Oncol 27 5 740 745 10.1200/jco.2008.16.3055 19114704 10.1200/JCO.2008.16.3055 1:CAS:528:DC%2BD1MXjsVCjs7o%3D
36. W Wick R Stupp A-C Beule J Bromberg A Wick U Ernemann M Platten C Marosi WP Mason M van den Bent M Weller C Rorden H-O Karnath Research tEOf, Cancer To, Group tNCIoCCT 2008 A novel tool to analyze MRI recurrence patterns in glioblastoma Neuro-Oncology 10 6 1019 1024 10.1215/15228517-2008-058 18676355 10.1215/15228517-2008-058
37. FM Iwamoto LE Abrey K Beal PH Gutin MK Rosenblum VE Reuter LM DeAngelis AB Lassman 2009 Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma Neurology 73 15 1200 1206 10.1212/WNL.0b013e3181bc0184 19822869 10.1212/WNL.0b013e3181bc0184 1:CAS:528:DC%2BD1MXht1antrfK
38. Narayana A, Kunnakkat SD, Medabalmi P, Golfinos J, Parker E, Knopp E, Zagzag D, Eagan P, Gruber D, Gruber ML Change in pattern of relapse after antiangiogenic therapy in high-grade glioma. Int J Radiat Oncol Biol Phys (in press, Corrected Proof)
39. G Bergers D Hanahan 2008 Modes of resistance to anti-angiogenic therapy Nat Rev Cancer 8 592 603 18650835 10.1038/nrc2442 1:CAS:528:DC%2BD1cXovV2lsrk%3D
40. U Bogdahn P Hau G Stockhammer NK Venkataramana AK Mahapatra A Suri A Balasubramaniam S Nair V Oliushine V Parfenov I Poverennova M Zaaroor P Jachimczak S Ludwig S Schmaus H Heinrichs K-H Schlingensiepen 2011 Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study Neuro-Oncology 13 1 132 142 20980335 10.1093/neuonc/noq142 1:CAS:528:DC%2BC3MXhvFOiur8%3D
41. R Stupp ME Hegi B Neyns R Goldbrunner U Schlegel PMJ Clement GG Grabenbauer AF Ochsenbein M Simon P-Y Dietrich T Pietsch C Hicking J-C Tonn A-C Diserens A Pica M Hermisson S Krueger M Picard M Weller 2010 Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma J Clin Oncol 28 16 2712 2718 20439646 10.1200/JCO.2009.26.6650 1:CAS:528:DC%2BC3cXoslyktLs%3D
42. Nghiemphu PL, Liu W, Lee Y, et al (2009) Bevacizumab and chemotherapy for recurrent glioblastoma. Neurology 72(14):1217-1222
43. Vredenburgh JJ, Desjardins A, Kirkpatrick JP, et al (in press) Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys